The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Sikirica, Mirko ^a   Iorga, Serban R ^b   Bancroft, Tim ^b   Potash, Jesse ^b  

^a GLAXOSMITHKLINE   (United States)

^b OPTUM   (United States)

Author keywords

Costs; Managed care; PAH; Pulmonary arterial hypertension; Resource use; Retrospective

Indexed keywords

ADULT; AGED; CHRONIC DISEASE; COHORT ANALYSIS; COST OF ILLNESS; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; HYPERTENSION; INSURANCE; MALE; MIDDLE AGED; PULMONARY HYPERTENSION; REIMBURSEMENT; UNITED STATES; UTILIZATION;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MIDDLE AGED; UNITED STATES;

EID: 84988600912     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-014-0676-0     Document Type: Article

References (24)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
2. Barst RJ, Ertel SI, Beghetti M, Ivy DD: Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011, 37:665-677.
3. Humbert M: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev 2010, 19:59-63.
4. McGoon MD, Kane GC: Pulmonary hypertension: diagnosis and management. Mayo Clin Proc 2009, 84:191-207.
5. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galiè N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001, 68:92-102.
6. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Halme M, Räisänen-Sokolowski A, Laitinen T, Morrell NW, Trembath RC: Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003, 40:865-871.
7. Nakanishi N, European Society of Cardiology, European Respiratory Society: ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergol Int 2009, 2011(60):419-424.
8. Tsai IC, Tsai WL, Wang KY, Chen MC, Liang KW, Tsai HY, Liao WC: Comprehensive MDCT evaluation of patients with pulmonary hypertension: diagnosing underlying causes with the updated Dana Point 2008 classification. AJR Am J Roentgenol 2011, 197:W471-W481.
9. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD: Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
10. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
11. McLaughlin VV: Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011, 20:262-269.
12. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
13. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
14. Hyduk A, Croft JB, Ayala C, Zheng K, Zheng ZJ, Mensah GA: Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 2005, 54:1-28.
15. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T: Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011, 27:1763-1768.
16. Copher R, Cerulli A, Watkins A, Laura Monsalvo M: Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ 2012, 15:947-955.
17. Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T: Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 2010, 13:393-402.
18. Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC: The cost to managed care of managing pulmonary hypertension. J Med Econ 2012, 15:500-508.
19. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T: Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy 2011, 9:293-303.
20. Health Insurance Portability and Accountability Act of 1996 [http://www. cms.gov/Regulations-and-Guidance/HIPAA-Administrative-Simplification/HIPAAGenInfo/TheHIPAALawandRelated-Information.html]
21. U.S. Department of Health & Human Services [http://answers.hhs.gov/ohrp/categories/1566]
22. Comorbidity Software Healthcare Cost and Utilization Project (HCUP) [www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp]
23. Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G: Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med 2012, 12:75.
24. Wilkens H, Grimminger F, Hoeper M, Stähler G, Ehlken B, Plesnila-Frank C, Berger K, Resch A, Ghofrani A: Burden of pulmonary arterial hypertension in Germany. Respir Med 2010, 104:902-910.